Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beeline, Cynergi Health Partners, Lightpoint Medical, Neupath Health, Opum, Provista Diagnostics, Thuasne Group, Todos Medical, Veon.
Cadila Healthcare Ltd. (also known as Zydus Cadila) has received emergency use authorization (EUA) in India for Zycov-D, making it the world’s first plasmid DNA vaccine for COVID-19. Besides the adult population, the Drug Controller General of India’s nod has also given the South Asian country its first COVID-19 vaccine for adolescents ages 12 to 18.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astellas, Biontech, Covis, Fibrogen, Gilead, Hebabiz, Ortho, Pfizer, Regeneron.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AB Science, Amyris, Bavarian Nordic, Bionova, Dialectic, Dyadic, Editas, Insilico, Kinarus, Marker, Palisade Bio, Sorrento, Telix.
The FDA has granted full approval to Pfizer Inc.’s COVID-19 vaccine in a move that is hoped will convince unvaccinated citizens that the shot is safe and effective. The mRNA vaccine, which will be branded as Comirnaty and was first developed by Germany’s Biontech SE, has been available since Dec. 11 last year under an emergency use authorization (EUA) and is the first to receive the FDA’s full endorsement.
Astrazeneca plc, en route to potentially delivering a new protection against COVID-19 for people inadequately protected by or unable to be vaccinated, has cleared a crucial hurdle with its long-acting combination therapy, AZD-7442, which met the goals of a phase III pre-exposure prophylaxis trial. The U.K.-based pharma’s readout arrived just as Regeneron Pharmaceuticals Inc. announced the MHRA’s conditional marketing authorization for its Roche Holding AG-partnered COVID-19 antibody therapy Ronapreve (casirivimab + imdevimab), also known as REGEN-COV.
Suzhou Abogen Biosciences Co. Ltd.’s $700 million series C fundraising provides tailwinds for the development of its messenger ribonucleic acid (mRNA) platform. The company plans to accelerate its COVID-19 mRNA vaccine clinical trial, develop other vaccine candidates and oncology programs.
The FDA’s pre-IND response to Virpax Pharmaceuticals Inc.’s MMS-019, a molecular masking spray being developed as an over-the-counter product to limit transmission of SARS and influenza, has the company breathing easier and ready to chase an NDA. Virpax is in a crowded field of 43 COVID-19 intranasal therapeutics and vaccine programs.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Coherus, Compugen, Intrabio, Janssen, Junshi, Nervgen, Nrx, Scioto, Zealand, Zhaoke.
RSS
